
Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials

Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.

Published: May 16th 2023 | Updated: